These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31706905)

  • 1. Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?
    Kashyap ML; Ganji S; Nakra NK; Kamanna VS
    J Clin Lipidol; 2019; 13(6):873-879. PubMed ID: 31706905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
    Ganji SH; Kashyap ML; Kamanna VS
    Metabolism; 2015 Sep; 64(9):982-90. PubMed ID: 26024755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A; Mosthael W; Sowa JP; Canbay A
    Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
    Amin NB; Saxena AR; Somayaji V; Dullea R
    Clin Ther; 2023 Jan; 45(1):55-70. PubMed ID: 36690550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
    Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
    Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real-time two-dimensional shear wave elastography: A randomized clinical trial.
    Soleimani D; Rezaie M; Rajabzadeh F; Gholizadeh Navashenaq J; Abbaspour M; Miryan M; Razmpour F; Ranjbar G; Rezvani R; Jarahi L; Hashemy SI; Goshayeshi L; Nematy M
    Phytother Res; 2021 Mar; 35(3):1669-1679. PubMed ID: 33166032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niacin regresses collagen content in human hepatic stellate cells from liver transplant donors with fibrotic non-alcoholic steatohepatitis (NASH).
    Ganji S; Hoa N; Kamanna J; Kamanna VS; Kashyap ML
    Am J Transl Res; 2022; 14(6):4006-4014. PubMed ID: 35836902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment?
    Nobili V; Alisi A; Mosca A; Crudele A; Zaffina S; Denaro M; Smeriglio A; Trombetta D
    Antioxid Redox Signal; 2019 Jul; 31(2):127-133. PubMed ID: 30588836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An energy-restricted high-protein diet supplemented with β-cryptoxanthin alleviated oxidative stress and inflammation in nonalcoholic fatty liver disease: a randomized controlled trial.
    Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K
    Nutr Res; 2020 Jan; 73():15-26. PubMed ID: 31841744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
    Pervez MA; Khan DA; Ijaz A; Khan S
    Turk J Gastroenterol; 2018 Mar; 29(2):170-176. PubMed ID: 29749323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selenium and selenoprotein P in nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Goulas A; Duntas L
    Hormones (Athens); 2020 Mar; 19(1):61-72. PubMed ID: 31493247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes.
    Zabihi NA; Pirro M; Johnston TP; Sahebkar A
    Curr Pharm Des; 2017; 23(7):969-982. PubMed ID: 27748192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.